Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis

Abstract Background LR11 (also called SorLA or SORL1) is a type I membrane protein, originally identified as a biomarker for atherosclerosis and Alzheimer's disease. We recently found that LR11 was specifically expressed in Diffuse Large B-cell lymphoma (DLBCL) cells, and high serum sLR11 concentrations in retrospective cohort indicated inferior survival. In this study, we prospectively validated the clinical impact of serum sLR11 in 97 patients with newly-diagnosed, untreated DLBCL. Results Serum sLR11 concentrations were increased in DLBCL patients compared to normal controls (mean ± SD: 21.2 ± 27.6 vs. 8.8 ± 1.8 ng/ml, P P  = 0.02). Increased serum sLR11 concentrations were affected by tumor burden and bone marrow invasion. The 2-y OS and PFS were significantly lower in patients with high sLR11 concentrations (≤ 18.1 ng/ml vs. > 18.1 ng/ml; 2-y OS: 89.0% vs. 56.4%, P P Conclusions Serum sLR11 is a tumor-derived biomarker for predicting the survival of newly diagnosed patients with DLBCL.